Skip to content

Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery

Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02372305
Enrollment
0
Registered
2015-02-26
Start date
2016-03-31
Completion date
2017-12-21
Last updated
2018-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasm

Brief summary

FlexHD and Alloderm are two common products used in breast reconstruction to hold tissue expanders and implants in place. There have been few chart review studies comparing outcomes between the two materials in breast reconstruction. These studies have determined there is no difference in complication rates between the two materials. However, there have never been any active studies to date. This study will serve as a randomized controlled trial comparing FlexHD and Alloderm. Several outcomes will be measured based off of inclusion and exclusion criteria to determine if either product is more suitable for use in breast reconstruction. This will be performed by randomly assigning patients to receive either FlexHD or Alloderm. Designated outcomes will be followed closely postoperatively. Outcomes will be statistically analyzed to determine complication rates between FlexHD and Alloderm and thus which product is better to use in breast reconstruction.

Detailed description

FlexHD and Alloderm are two common products used in breast reconstruction to hold tissue expanders and implants in place. There have been few chart review studies comparing outcomes between the two materials in breast reconstruction. These studies have determined there is no difference in complication rates between the two materials. However, there have never been any active studies to date. This study will serve as a randomized controlled trial comparing FlexHD and Alloderm. Several outcomes will be measured based off of inclusion and exclusion criteria to determine if either product is more suitable for use in breast reconstruction. This will be performed by randomly assigning patients to receive either FlexHD or Alloderm. Designated outcomes will be followed closely postoperatively. Outcomes will be statistically analyzed to determine complication rates between FlexHD and Alloderm and thus which product is better to use in breast reconstruction

Interventions

BIOLOGICALFlexHD

Patients will be randomized to receive FlexHD.

BIOLOGICALAlloderm

Patient will be randomized to receive Alloderm.

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* BMI\<30 * No Prior Breast Radiation * No Prior Breast Reduction * No Diabetes Mellitus (IDDM and non-IDDM) * Non-smoker or quit \>6 weeks prior * No breast implants or prior breast implants * No inflammatory or autoimmune disorders * No current anticoagulation therapy * No current pregnant

Exclusion criteria

* BMI \> 30 * Prior Breast Radiation * Diabetes Mellitus - IDDM and non IDDM * Prior Breast Reduction * Active Smoker or Recently Quit \<6 weeks * Prior Breast Implants * Inflammatory/Autoimmune Condition (ex. Lupus) * Current Anticoagulation Therapy * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Wound DehiscenceOne Yeartime frame.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026